Neoantigens and shared MICB α3 antigen dual-targeted vaccine generates potent antitumor immunity

ABSTRACT: Immune suppression is one of the primary obstacles in neoantigen immunotherapy because tumors can rapidly adapt by reducing MHC-I expression or antigen presentation. Here, we developed a novel immunotherapy strategy that combined vaccination of neoantigens with MICB α3 antigen, by using bacterial outer membrane vesicles (OMVs) as a versatile vector and adjuvant. This approach aims to simultaneously induce a neoantigen-specific cellular immune response and an anti-MICB α3 humoral immune response, enhancing the recognition and killing of tumor cells by immune cells. This strategy significantly improves the infiltration of neoantigen-specific T cells and NK cells, and reverses immunosuppression across various preclinical models. Mechanistically, ILC1s characterized by high GZMA/GZMB expressio

SUBMITTER: Ruijing Tang 

PROVIDER: S-SCDT-10_1038-S44321-026-00424-6 | biostudies-other |

REPOSITORIES: biostudies-other